Xcout IntelFoment Bio, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Foment Bio, Inc. among biotechnology companies — ranked by similarity to what Foment Bio, Inc. actually does, not by market-cap band.
Subscribe to see Foment Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Foment Bio, Inc.
Foment Bio, Inc. is a biotechnology company developing non-viral, transient gene therapy constructs designed to stimulate in vivo regenerative exosome production. The company's therapies aim to restore tissue microvasculature, resolve inflammation, and rescue cells to treat age-related and cardiometabolic conditions such as heart failure, chronic kidney disease, erectile dysfunction, and impaired wound healing.
Foment Bio, Inc. at a glance
Foment Bio, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $542,550 in May 2024. Xcout tracks 4 named people at Foment Bio, Inc., including Ben Chlebina (CEO).
Foment Bio, Inc. leadership
- Ben ChlebinaCEO
- Ben ChlebinaCEO, CO-FOUNDER
- Dr. Marc PennCMO, CO-FOUNDER
- Mark D'AndreaVP OF CMC & QUALITY
Foment Bio, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $542,550 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Foment Bio, Inc. competitors
Ranked by semantic similarity — how close each company is to Foment Bio, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Rejuvenate Bio, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, United States, specializing in innovative gene therapy applications.
Similar biotechnology company
Frontier Bio develops engineered human tissues and vascular grafts to address cardiovascular disease and eliminate the need for organ donors and animal testing. The company provides tissue-engineered blood vessels for vascular grafts and commercializes human-based tissue models and services for preclinical testing.
Similar biotechnology company
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Similar biotechnology company
Endogena Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Zürich, Switzerland, that discovers and develops first-in-class endogenous regenerative medicines to repair tissues.
Similar biotechnology company
Imagine Pharma LLC is a biotechnology company that develops novel polypeptide-based platforms focused on oral delivery for biologic drugs, therapeutics for various disease states, and regenerative medicine. The company aims to create first-in-class treatments for conditions such as diabetes and wound healing, alongside offering oral peptide dietary supplements and functional ingredients for consumers.
Similar biotechnology company
Federation Bio is a U.S. biotechnology company developing live biotherapeutic products based on defined microbial communities to treat diseases. Its work has focused on microbiome-based therapies for metabolic and other serious disorders, serving patients with conditions that may benefit from engineered microbial consortia.
Biotech
CiRC Biosciences is a privately held regenerative medicine and cell therapy company founded in 2019 and based in Chicago, Illinois, focused on developing cellular reprogramming solutions for degenerative diseases.
Similar biotechnology company
Immunis, Inc. is a private, clinical-stage biotechnology company founded in 2019 and headquartered in Irvine, California, pursuing novel secretome-based therapeutics for age-related diseases.
Life Science
Angiocrine Bioscience, Inc. is a private, clinical-stage biotechnology company based in San Diego, California, that develops engineered endothelial cell therapies.
Biotech
Endsulin, Inc. is a biotechnology company developing a liver-directed gene therapy for Type 1 Diabetes. Its proprietary technology aims to re-engineer liver cells to restore the body's natural ability to produce and regulate insulin, eliminating the need for artificial insulin delivery methods.
Health & Life Sciences
Elevian, Inc. is a biotechnology research company dedicated to developing new medicines that promote recovery and regeneration.
Similar biotechnology company
Excision BioTherapeutics Inc. is a San Francisco-based clinical-stage biotechnology company focused on developing advanced gene editing therapeutics to treat infectious diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Foment Bio, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Foment Bio, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →